{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:43:40Z","timestamp":1790747020747,"version":"4.1.0"},"reference-count":65,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for glycaemic control in patients with type 2 diabetes, have demonstrated significant cardiometabolic benefits beyond glucose regulation. These agents have multiple effects, including reducing body weight, improving insulin sensitivity, anti-inflammatory properties and enhancing endothelial function. All these mechanisms are potentially beneficial in patients with heart failure (HF), specifically those with HF with preserved left ventricular ejection fraction. Recent trials, including STEP-HFpEF and SUMMIT, underscore the efficacy of GLP-1 RAs in improving quality of life and exercise capacity, as well as possibly reducing major adverse cardiovascular events. Furthermore, these trials demonstrated improvements in other endpoints, such plasma N-terminal pro B-type natriuretic peptide, troponin and C-reactive protein concentrations, consistent with the beneficial effects of GLP-1 RAs on myocardial function and inflammation. Further data are needed regarding the effects of GLP-1 RAs on cardiovascular outcomes, and possibly in a broader range of patients with HF, such as those with HF reduced ejection fraction and\/or patients without obesity.<\/jats:p>","DOI":"10.15420\/cfr.2025.10","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T16:27:28Z","timestamp":1755188848000},"source":"Crossref","is-referenced-by-count":6,"title":["Understanding the Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Heart Failure"],"prefix":"10.15420","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-8336","authenticated-orcid":false,"given":"Giovanni Battista","family":"Bonfioli","sequence":"first","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9298-7871","authenticated-orcid":false,"given":"Matteo","family":"Pagnesi","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-2857","authenticated-orcid":false,"given":"Daniela","family":"Tomasoni","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-962X","authenticated-orcid":false,"given":"Amina","family":"Rakisheva","sequence":"additional","affiliation":[{"name":"City Cardiology Center, Almaty, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021;23:352\u201380. https:\/\/doi.org\/10.1002\/ejhf.2115; PMID:\u00a033605000.","DOI":"10.1002\/ejhf.2115"},{"key":"ref1","unstructured":"McDonagh TA, Metra M, Adamo M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID:\u00a034447992."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272\u201387. https:\/\/doi.org\/10.1093\/cvr\/cvac013; PMID:\u00a035150240.","DOI":"10.1093\/cvr\/cvac013"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Ahmad T, Alexander KM, et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail 2023;29:1412\u201351. https:\/\/doi.org\/10.1016\/j.cardfail.2023.07.006; PMID:\u00a037797885.","DOI":"10.1016\/j.cardfail.2023.07.006"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Khan MS, Shahid I, Bennis A, et al. Global epidemiology of heart failure. Nat Rev Cardiol 2024;21:717\u201334. https:\/\/doi.org\/10.1038\/s41569-024-01046-6; PMID:\u00a038926611.","DOI":"10.1038\/s41569-024-01046-6"},{"key":"ref5","unstructured":"McDonagh TA, Metra M, Adamo M, et al. Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195; PMID:\u00a037622666."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Marx N, Husain M, Lehrke M, et al. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 2022;146:1882\u201394. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059595; PMID:\u00a036508493.","DOI":"10.1161\/CIRCULATIONAHA.122.059595"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Bonfioli GB, Rodella L, Metra M, Vizzardi E. GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction. Heart Fail Rev 2025;30:131\u20136. https:\/\/doi.org\/10.1007\/s10741-024-10450-6; PMID:\u00a039425816.","DOI":"10.1007\/s10741-024-10450-6"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Cimino G, Vaduganathan M, Lombardi CM, et al. Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists. ESC Heart Fail 2024;11:649\u201361. https:\/\/doi.org\/10.1002\/ehf2.14560; PMID:\u00a038093506.","DOI":"10.1002\/ehf2.14560"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1509225; PMID:\u00a026630143.","DOI":"10.1056\/NEJMoa1509255"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827; PMID:\u00a027295427.","DOI":"10.1056\/NEJMoa1603827"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141; PMID:\u00a027633186.","DOI":"10.1056\/NEJMoa1607141"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1612917; PMID:\u00a028910237.","DOI":"10.1056\/nejmoa1612917"},{"key":"ref13","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:1519\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X; PMID:\u00a030291013."},{"key":"ref14","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3; PMID:\u00a031189511."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021;385:896\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa2108269; PMID:\u00a034215025.","DOI":"10.1056\/nejmoa2108269"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381:841\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1901118; PMID:\u00a031185157.","DOI":"10.1056\/NEJMoa1901118"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Sisson EM. Liraglutide: clinical pharmacology and considerations for therapy. Pharmacotherapy 2011;31:896\u2013911. https:\/\/doi.org\/10.1592\/phco.31.9.896; PMID: 21923591.","DOI":"10.1592\/phco.31.9.896"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Hall S, Isaacs D, Clements JN. Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. Clin Pharmacokinet 2018;57:1529\u201338. https:\/\/doi.org\/10.1007\/s40262-018-0668-z; PMID: 29915923.","DOI":"10.1007\/s40262-018-0668-z"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 2021;46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102; PMID: 33068776.","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Min JS, Jo SJ, Lee S, et al. A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist. Drug Des Devel Ther 2025;19:3509\u201337. https:\/\/doi.org\/10.2147\/DDDT.S506957; PMID: 40330819.","DOI":"10.2147\/dddt.s506957"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Schneck K, Urva S. Population pharmacokinetics of the GIP\/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol 2024;13:494-503. doi: 10.1002\/psp4.1309; PMID: 38356317.","DOI":"10.1002\/psp4.13099"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Vaduganathan M. GLP-1 receptor agonists in heart failure. Lancet 2024;404:727\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(24)01598-8; PMID:\u00a039181582.","DOI":"10.1016\/s0140-6736(24)01598-8"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 2016;39(Suppl 2):S244\u201352. https:\/\/doi.org\/10.2337\/dcS15-3015; PMID:\u00a027440839.","DOI":"10.2337\/dcs15-3015"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Pandey A, LaMonte M, Klein L, et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol 2017;69:1129\u201342. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.081; PMID:\u00a028254175.","DOI":"10.1016\/j.jacc.2016.11.081"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 2024;384:e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410; PMID:\u00a038286487.","DOI":"10.1136\/bmj-2023-076410"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond) 2025;49:433\u201351. https:\/\/doi.org\/10.1038\/s41366-024-01473-y; PMID:\u00a038302593.","DOI":"10.1038\/s41366-024-01473-y"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394; PMID: 40353578.","DOI":"10.1056\/nejmoa2416394"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500\u20138. https:\/\/doi.org\/10.1001\/jama.2016.10260; PMID:\u00a027483064.","DOI":"10.1001\/jama.2016.10260"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) \u2013 a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69\u201377. https:\/\/doi.org\/10.1002\/ejhf.657; PMID:\u00a027790809.","DOI":"10.1002\/ejhf.657"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Sharma A, Butler J, et al. Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure. J Clin Endocrinol Metab 2023;109:4\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgad398; PMID:\u00a037409733.","DOI":"10.1210\/clinem\/dgad398"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Neves JS, Zannad F, Butler J, et al. Should the SELECT trial make us comfortable using GLP-1 receptor agonists in HFrEF? J Am Coll Cardiol 2024;84:1119\u201322. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.026; PMID:\u00a039115523.","DOI":"10.1016\/j.jacc.2024.06.026"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Pugliese NR, Paneni F, Mazzola M, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail 2021;23:1858\u201371. https:\/\/doi.org\/10.1002\/ejhf.2337; PMID:\u00a034427016.","DOI":"10.1002\/ejhf.2337"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Iacobellis G, Villasante Fricke AC. Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity. J Endocr Soc 2020;4:bvz042. https:\/\/doi.org\/10.1210\/JENDSO\/BVZ042; PMID:\u00a032190806.","DOI":"10.1210\/jendso\/bvz042"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Iacobellis G, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. Obesity (Silver Spring) 2017;25:311\u20136. https:\/\/doi.org\/10.1002\/oby.21718; PMID:\u00a028124506.","DOI":"10.1002\/oby.21718"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Dutour A, Abdesselam I, Ancel P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 2016;18:882\u201391. https:\/\/doi.org\/10.1111\/dom.12680; PMID:\u00a027106272.","DOI":"10.1111\/dom.12680"},{"key":"ref36","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular\u2013kidney\u2013metabolic health: a presidential advisory from the American Heart Association. Circulation 2023;148:1606\u201335. https:\/\/doi.org\/10.1161\/CIR.0000000000001184; PMID:\u00a037807924."},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Ostrominski JW, Claggett BL, Miao ZM, et al. Cardiovascular\u2013kidney\u2013metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: a trial-level analysis. J Am Coll Cardiol 2024;84:223\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.005; PMID:\u00a038744407.","DOI":"10.1016\/j.jacc.2024.05.005"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Peikert A, Vaduganathan M, Claggett BL, et al. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the Paragon-HF trial. Eur Heart J 2025;46:2372\u201390. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf057; PMID:\u00a039873282.","DOI":"10.1093\/eurheartj\/ehaf057"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Metra M, Cotter G, Gheorghiade M, et al. The role of the kidney in heart failure. Eur Heart J 2012;33:2135\u201342. https:\/\/doi.org\/10.1093\/eurheartj\/ehs205; PMID:\u00a022888113.","DOI":"10.1093\/eurheartj\/ehs205"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Greco EV, Russo G, Giandalia A, et al. GLP-1 receptor agonists and kidney protection. Medicina (Kaunas) 2019;55:233. https:\/\/doi.org\/10.3390\/medicina55060233; PMID:\u00a031159279.","DOI":"10.3390\/medicina55060233"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377:839\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1616011; PMID:\u00a028854085.","DOI":"10.1056\/nejmoa1616011"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347; PMID:\u00a038785209.","DOI":"10.1056\/nejmoa2403347"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Puglisi S, Rossini A, Poli R, et al. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin\u2013angiotensin\u2013aldosterone system. Front Endocrinol (Lausanne) 2021;12:738848. https:\/\/doi.org\/10.3389\/fendo.2021.738848; PMID:\u00a034745006.","DOI":"10.3389\/fendo.2021.738848"},{"key":"ref44","unstructured":"Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963; PMID:\u00a037622681."},{"key":"ref45","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024;390:1394\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2313917; PMID:\u00a038587233."},{"key":"ref46","unstructured":"Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 2024;403:1635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(24)00469-0; PMID:\u00a038599221."},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Bray JJH, Foster-Davies H, Salem A, et al. Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab 2021;23:1806\u201322. https:\/\/doi.org\/10.1111\/dom.14399; PMID:\u00a033830637.","DOI":"10.1111\/dom.14399"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"W\u00f3jcicka G, Pradiuch A, Fornal E, et al. The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome. Biochem Pharmacol 2023;214:115637. https:\/\/doi.org\/10.1016\/j.bcp.2023.115637; PMID:\u00a037290595.","DOI":"10.1016\/j.bcp.2023.115637"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Withaar C, Meems LMG, Markousis-Mavrogenis G, et al. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovasc Res 2021;117:2108\u201324. https:\/\/doi.org\/10.1093\/cvr\/cvaa256; PMID:\u00a032871009.","DOI":"10.1093\/cvr\/cvaa256"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340\u201350. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.739938; PMID:\u00a018427132.","DOI":"10.1161\/circulationaha.107.739938"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Koska J, Sands M, Burciu C, et al. Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes 2015;64:2624\u201335. https:\/\/doi.org\/10.2337\/db14-0976; PMID:\u00a025720388.","DOI":"10.2337\/db14-0976"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Wei R, Ma S, Wang C, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab 2016;310:E947\u201357. https:\/\/doi.org\/10.1152\/ajpendo.00400.2015; PMID:\u00a027072494.","DOI":"10.1152\/ajpendo.00400.2015"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Anker SD, Usman MS, Anker MS, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail 2023;25:936\u201355. https:\/\/doi.org\/10.1002\/ejhf.2894; PMID:\u00a037461163.","DOI":"10.1002\/ejhf.2894"},{"key":"ref54","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023;44:4043\u2013140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192; PMID:\u00a037622663."},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Villaschi A, Ferrante G, Cannata F, et al. GLP-1-RA and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis. Clin Res Cardiol 2024;113:898\u2013909. https:\/\/doi.org\/10.1007\/s00392-023-02362-6; PMID:\u00a038252145.","DOI":"10.1007\/s00392-023-02362-6"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563; PMID:\u00a037952131.","DOI":"10.1056\/NEJMoa2307563"},{"key":"ref57","unstructured":"Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 2024;404:773\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(24)01498-3; PMID:\u00a039181597."},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027; PMID:\u00a039555826.","DOI":"10.1056\/NEJMoa2410027"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium\u2013glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:422\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031; PMID:\u00a032000955.","DOI":"10.1016\/j.jacc.2019.11.031"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Patel R, Wadid M, Makwana B, et al. GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors. JACC Heart Fail 2024;12:1814\u201326. https:\/\/doi.org\/10.1016\/j.jchf.2024.07.006; PMID:\u00a039207323.","DOI":"10.1016\/j.jchf.2024.07.006"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Neuen BL, Heerspink HJL, Vart P, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024;149:450\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067584; PMID:\u00a037952217.","DOI":"10.1161\/circulationaha.123.067584"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Ostrominski JW, Solomon SD, Vaduganathan M. Heart failure with preserved ejection fraction therapy: combining sodium\u2013glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. Eur Heart J 2024;45:2748\u201351. https:\/\/doi.org\/10.1093\/eurheartj\/ehae414; PMID:\u00a038982938.","DOI":"10.1093\/eurheartj\/ehae414"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Weiss T, Yang L, Carr RD, et al. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Res Care 2022;10:e002517. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002517; PMID:\u00a035101924.","DOI":"10.1136\/bmjdrc-2021-002517"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Thomsen RW, Mailhac A, L\u00f8hde JB, Potteg\u00e5rd A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab 2025;27(Suppl 2):66\u201388. https:\/\/doi.org\/10.1111\/dom.16364; PMID:\u00a040196933.","DOI":"10.1111\/dom.16364"}],"container-title":["Cardiac Failure Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T16:27:33Z","timestamp":1755188853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":65,"URL":"https:\/\/doi.org\/10.15420\/cfr.2025.10","relation":{},"ISSN":["2057-7559","2057-7540"],"issn-type":[{"value":"2057-7559","type":"electronic"},{"value":"2057-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"article-number":"e19"}}